Adma Biologics (ADMA) Revenue (2011 - 2025)

Adma Biologics' Revenue history runs 14 years deep, the most recent figure standing at $139.2 million for Q4 2025.

• Quarterly Revenue rose 18.39% year-over-year to $139.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $510.2 million (up 19.63% YoY) and the FY2025 annual result came in at $510.2 million, up 19.63% from the prior year.
• Revenue was $139.2 million for Q4 2025 at Adma Biologics, up from $134.2 million in the prior quarter.
• Across five years, Revenue topped out at $139.2 million in Q4 2025 and bottomed at $16.0 million in Q1 2021.
• A 5-year average of $77.1 million and a median of $74.5 million in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue surged 320.63% — and 2023, when it decreased 19.84%.
• Adma Biologics' Revenue stood at $55.0 million in 2021, then retreated by 9.12% to $50.0 million in 2022, then jumped by 47.86% to $73.9 million in 2023, then surged by 59.06% to $117.5 million in 2024, then grew by 18.39% to $139.2 million in 2025.
• Business Quant data shows ADMA's Revenue at $139.2 million in Q4 2025, $134.2 million in Q3 2025, and $122.0 million in Q2 2025.